Datapoint: Imbruvica Scores First Pediatric Nod

The FDA last week approved Johnson & Johnson’s Imbruvica for the treatment of chronic graft-versus-host disease (cGVHD) in pediatric patients following the failure of at least one prior treatment. This is the first pediatric nod for the kinase inhibitor. Imbruvica became the first FDA-approved cGVHD therapy in August 2017. For that indication, it holds covered or better status for virtually all (99%) of insured lives under the pharmacy benefit. 16.5% of insured lives have preferred access to Imbruvica, growing to 42.9% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 8/29/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 7

Datapoint: Gilead Scores Broader Breast Cancer Nod for Trodelvy

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 6

Datapoint: New Mexico Cancels Medicaid RFP

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today